384 related articles for article (PubMed ID: 26725216)
1. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.
Hayes TK; Neel NF; Hu C; Gautam P; Chenard M; Long B; Aziz M; Kassner M; Bryant KL; Pierobon M; Marayati R; Kher S; George SD; Xu M; Wang-Gillam A; Samatar AA; Maitra A; Wennerberg K; Petricoin EF; Yin HH; Nelkin B; Cox AD; Yeh JJ; Der CJ
Cancer Cell; 2016 Jan; 29(1):75-89. PubMed ID: 26725216
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.
Ozkan-Dagliyan I; Diehl JN; George SD; Schaefer A; Papke B; Klotz-Noack K; Waters AM; Goodwin CM; Gautam P; Pierobon M; Peng S; Gilbert TSK; Lin KH; Dagliyan O; Wennerberg K; Petricoin EF; Tran NL; Bhagwat SV; Tiu RV; Peng SB; Herring LE; Graves LM; Sers C; Wood KC; Cox AD; Der CJ
Cell Rep; 2020 Jun; 31(11):107764. PubMed ID: 32553168
[TBL] [Abstract][Full Text] [Related]
3. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.
Vaseva AV; Blake DR; Gilbert TSK; Ng S; Hostetter G; Azam SH; Ozkan-Dagliyan I; Gautam P; Bryant KL; Pearce KH; Herring LE; Han H; Graves LM; Witkiewicz AK; Knudsen ES; Pecot CV; Rashid N; Houghton PJ; Wennerberg K; Cox AD; Der CJ
Cancer Cell; 2018 Nov; 34(5):807-822.e7. PubMed ID: 30423298
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
5. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
[TBL] [Abstract][Full Text] [Related]
6. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
7. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
8. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.
Waters AM; Khatib TO; Papke B; Goodwin CM; Hobbs GA; Diehl JN; Yang R; Edwards AC; Walsh KH; Sulahian R; McFarland JM; Kapner KS; Gilbert TSK; Stalnecker CA; Javaid S; Barkovskaya A; Grover KR; Hibshman PS; Blake DR; Schaefer A; Nowak KM; Klomp JE; Hayes TK; Kassner M; Tang N; Tanaseichuk O; Chen K; Zhou Y; Kalkat M; Herring LE; Graves LM; Penn LZ; Yin HH; Aguirre AJ; Hahn WC; Cox AD; Der CJ
Cell Rep; 2021 Jun; 35(13):109291. PubMed ID: 34192548
[TBL] [Abstract][Full Text] [Related]
9. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
Adamopoulos C; Cave DD; Papavassiliou AG
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
[TBL] [Abstract][Full Text] [Related]
11. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
12. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
13. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
Dogan Turacli I; Ozkan AC; Ekmekci A
Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
[TBL] [Abstract][Full Text] [Related]
14. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.
Collisson EA; Trejo CL; Silva JM; Gu S; Korkola JE; Heiser LM; Charles RP; Rabinovich BA; Hann B; Dankort D; Spellman PT; Phillips WA; Gray JW; McMahon M
Cancer Discov; 2012 Aug; 2(8):685-93. PubMed ID: 22628411
[TBL] [Abstract][Full Text] [Related]
15. Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells.
Lee S; Heinrich EL; Lu J; Lee W; Choi AH; Luu C; Chung V; Fakih M; Kim J
Pancreas; 2016 Feb; 45(2):286-92. PubMed ID: 26262587
[TBL] [Abstract][Full Text] [Related]
16. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
17. ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells.
Khandakar GI; Satoh R; Takasaki T; Fujitani K; Tanabe G; Sakai K; Nishio K; Sugiura R
Cells; 2022 Feb; 11(4):. PubMed ID: 35203351
[TBL] [Abstract][Full Text] [Related]
18. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
20. Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.
Brown WS; McDonald PC; Nemirovsky O; Awrey S; Chafe SC; Schaeffer DF; Li J; Renouf DJ; Stanger BZ; Dedhar S
Cell Rep Med; 2020 Nov; 1(8):100131. PubMed ID: 33294856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
